Targeting Mitochondrial Dysfunction

Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.

View Candidate
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.K

Poxel has also established a Japanese subsidiary in Tokyo Both events are strategic commitments to the Japanese and Asian markets Lyon, France, September 13, 2018 – POXEL SA (Euronext – POXEL -…

Read this Press Release: Poxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.K

Poxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

LYON, France--(BUSINESS WIRE)--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes…

Read this Press Release: Poxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference
Click here to show the previous slide Click here to show the next slide

Upcoming Events

Poxel H1 Conference Call French

Poxel H1 Conference Call English

Click here to show the previous slide Click here to show the next slide